June 7, 1977


Release # 77-059

WASHINGTON, D.C. (June 7) -- Bristol Myers Products, a division of Bristol Myers Company, and the Consumer Product Safety Commission (CPSC) announced today a product substitution of the company's 225 tablet package size and 375 tablet size of Excedrin analgesic tablets which were distributed nationwide prior to April 1977. CPSC testing found same packages for this product failed to comply with Federal regulations requiring that the packages be child-resistant.

The product substitution covers warehouse inventories of those major wholesale and retail customers handling approximately 81% of the merchandise. Existing inventories of these packages are being retrieved and replaced by upgraded packages which were tested by Bristol Myers to assure CPSC compliance. The product substitution will involve approximately 150,000 packages and will be completed by the middle of June. These two sizes represent less than 3% of Excedrin analgesic annual unit sales volume.

Bristol Myers Products, in addition, has improved its packages for these sizes of Excedrin analgesic products and has expanded its quality control program to reduce the likelihood of similar situations arising in the future.

This program is not a substitute for any legal action which may be deemed necessary by CPSC.